ARTICLE | Clinical News
Revestive regulatory update
June 6, 2016 7:00 AM UTC
EMA’s CHMP recommended expanding the label of Shire’s Revestive teduglutide to treat short bowel syndrome (SBS) to include patients ages 1-17. The analog of glucagon-like peptide-2 (GLP-2) is approve...